<DOC>
	<DOCNO>NCT00757237</DOCNO>
	<brief_summary>The purpose study assess comparative safety effectiveness aztreonam inhalation solution versus tobramycin inhalation solution adult pediatric patient cystic fibrosis ( CF ) pulmonary Pseudomonas aeruginosa ( PA ) infection .</brief_summary>
	<brief_title>Aztreonam Inhalation Solution v Tobramycin Inhalation Solution Patients With Cystic Fibrosis &amp; Pseudomonas Aeruginosa</brief_title>
	<detailed_description>Number Subjects Planned : Approximately 240 randomized patient Target Population : CF patient &gt; = 6 year age stable pulmonary disease , study entry recent positive sputum culture PA previously treat aerosolized antibiotic without demonstration drug intolerance . The randomized phase study , use hypothesis test , enrolled participant United States ( US ) EU . An open-label , single-arm extension available participant EU complete least one course AZLI TIS randomize portion study . These participant eligible receive 3 additional cycle AZLI 28-day , intermittent , repeat treatment regimen . Results extension phase available first quarter ( Q1 ) 2012 . Randomized Phase Study Design ( US EU ) : This open-label , multicenter , randomize , parallel group study . The study design consist 2 treatment arm 28-day , intermittent , repeat treatment regimen : aztreonam inhalation solution ( AZLI ) tobramycin inhalation solution ( TIS ) . The total study period 26 week . The study schedule include 9 visit - Screening , Baseline , Day 14 , Day 28 , follow visit every 28 day end study .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Respiratory Aspiration</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Tobramycin</mesh_term>
	<mesh_term>Aztreonam</mesh_term>
	<mesh_term>Antibiotics , Antitubercular</mesh_term>
	<criteria>Males female age 6 year old Subjects CF diagnose one following : documented sweat chloride &gt; = 60 mEq/L quantitative pilocarpine iontophoresis test , document sweat sodium &gt; = 60 mmol/L , 2 well characterize genetic mutation Cystic Fibrosis Transmembrane Conductance Regulator ( CFTR ) gene , abnormal nasal potential difference accompany symptom characteristic CF Documented PA expectorate sputum throat swab culture within 3 month prior Visit 1 Visit 1 Subjects must able provide write informed consent/assent prior study related procedure ; parent/guardian must able give write informed consent necessary prior study related procedure Subjects must receive previous treatment aerosolize antibiotic without demonstration drug intolerance FEV1 &lt; = 75 % predict Visit 1 Ability perform reproducible pulmonary function test Chest radiograph Visit 1 without significant acute finding ( eg , infiltrate [ lobar diffuse interstitial ] , pleural effusion , pneumothorax ) ; chest radiograph magnetic resonance image ( MRI ) obtain within 180 day prior Visit 1 without acute finding significant intercurrent illness ; chronic , stable finding ( eg , chronic scar atelectasis ) allow Current use oral corticosteroid dos exceed equivalent 10 mg prednisone day 20 mg prednisone every day History sputum throat swab culture yield B. cepacia previous 2 year Current requirement daily continuous oxygen supplementation requirement 2 L/minute night Administration investigational drug device within 28 day Visit 1 within 6 halflives investigational drug ( whichever longer ) Known local systemic hypersensitivity monobactam antibiotic Known allergies/intolerance tobramycin Inability tolerate inhalation short act beta agonist Changes initiation chronic azithromycin treatment within 28 day prior Visit 1 Administration antipseudomonal antibiotic inhalation , intravenous oral route within 14 day prior Randomization/Visit 2 Changes antimicrobial , bronchodilator ( BD ) , dornase alfa , corticosteroid medication within 7 day prior Visit 1 Changes physiotherapy technique schedule within 7 day prior Visit 1 History lung transplantation Abnormal renal hepatic function serum chemistry Visit 1 , define aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) &gt; 5 time upper limit normal range ( ULN ) creatinine &gt; 2 time ULN Positive pregnancy test Visit 1 ; woman childbearing potential test Female childbearing potential lactating ( opinion investigator ) practice acceptable method birth control ; female subject utilize hormonal contraceptive one birth control method must use method least 3 month study dose Any serious active medical psychiatric illness , opinion investigator , would interfere patient treatment , assessment , compliance protocol</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>aztreonam lysine</keyword>
	<keyword>tobramycin inhalation solution</keyword>
	<keyword>tobramycin nebuliser solution</keyword>
	<keyword>cystic fibrosis</keyword>
	<keyword>pseudomonas aeruginosa</keyword>
	<keyword>lung infection</keyword>
	<keyword>CFQ-R</keyword>
	<keyword>inhale antibiotic</keyword>
</DOC>